|
Synonyms: APOC-III antisense inhibitor | ISIS 304801 | ISIS-APOCIIIRx | Waylivra®
volanesorsen is an approved drug (EMA (2019))
Compound class:
Nucleic acid
Comment: Volanesorsen is an antisense oligonucleotide (ASO) designed to reduce levels of apolipoprotein C-III (APOC3) in patients with elevated blood triglyceride levels [3]. Reducing triglycerides via APOC3 could be beneficial in patients with inherited hypertriglyceridemia (e.g. those with familial chylomicronemia syndrome, FCS) [1]. The role of APOC3 in hypertriglyceridemia and the effects APOC3 ASO use are reviewed in [5].
HELM annotation for this RNA (from PubChem) is RNA1{[MOE](A).[sp][MOE](G).[sp][MOE]([5meC]).[sp][MOE](T).[sp][MOE](T).[sp][dR]([5meC]).[sp][dR](T).[sp][dR](T).[sp][dR](G).[sp][dR](T).[sp][dR]([5meC]).[sp][dR]([5meC]).[sp][dR](A).[sp][dR](G).[sp][dR]([5meC]).[sp][MOE](T).[sp][MOE](T).[sp][MOE](T).[sp][MOE](A).[sp][MOE](T)}$$$$. |
|
|||||||||||||||
| References |
|
1. Gaudet D, Brisson D, Tremblay K, Alexander VJ, Singleton W, Hughes SG, Geary RS, Baker BF, Graham MJ, Crooke RM et al.. (2014)
Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med, 371 (23): 2200-6. [PMID:25470695] |
|
2. Gouni-Berthold I, Alexander VJ, Yang Q, Hurh E, Steinhagen-Thiessen E, Moriarty PM, Hughes SG, Gaudet D, Hegele RA, O'Dea LSL et al.. (2021)
Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol, 9 (5): 264-275. [PMID:33798466] |
|
3. Graham MJ, Lee RG, Bell 3rd TA, Fu W, Mullick AE, Alexander VJ, Singleton W, Viney N, Geary R, Su J et al.. (2013)
Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res, 112 (11): 1479-90. [PMID:23542898] |
|
4. Hegele RA, Berberich AJ, Ban MR, Wang J, Digenio A, Alexander VJ, D'Erasmo L, Arca M, Jones A, Bruckert E et al.. (2018)
Clinical and biochemical features of different molecular etiologies of familial chylomicronemia. J Clin Lipidol, 12 (4): 920-927.e4. [PMID:29748148] |
|
5. Lee RG, Crosby J, Baker BF, Graham MJ, Crooke RM. (2013)
Antisense technology: an emerging platform for cardiovascular disease therapeutics. J Cardiovasc Transl Res, 6 (6): 969-80. [PMID:23856914] |
|
6. Paik J, Duggan S. (2019)
Volanesorsen: First Global Approval. Drugs, 79 (12): 1349-1354. [PMID:31301033] |
|
7. Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, Yang Q, Hughes SG, Geary RS, Arca M et al.. (2019)
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. N Engl J Med, 381 (6): 531-542. [PMID:31390500] |